Literature DB >> 30257979

Haploinsufficiency of Insm1 Impairs Postnatal Baseline β-Cell Mass.

Weihua Tao1, Yao Zhang2, Lijuan Ma1,3, Chujun Deng1,3, Hualin Duan1, Xuehua Liang1, Rui Liao1, Shaoqiang Lin1, Tao Nie1,4, Wanqun Chen3, Cunchuan Wang1, Carmen Birchmeier2, Shiqi Jia5,2,4.   

Abstract

Baseline β-cell mass is established during the early postnatal period when β-cells expand. In this study, we show that heterozygous ablation of Insm1 decreases baseline β-cell mass and subsequently impairs glucose tolerance. When exposed to a high-fat diet or on an ob/ob background, glucose intolerance was more severe in Insm1+/lacZ mice compared with Insm1+/+ mice, although no further decrease in the β-cell mass was detected. In islets of early postnatal Insm1+/lacZ mice, the cell cycle was prolonged in β-cells due to downregulation of the cell cycle gene Ccnd1 Although Insm1 had a low affinity for the Ccnd1 promoter compared with other binding sites, binding affinity was strongly dependent on Insm1 levels. We observed dramatically decreased binding of Insm1 to the Ccnd1 promoter after downregulation of Insm1 expression. Furthermore, downregulation of Ccnd1 resulted in a prolonged cell cycle, and overexpression of Ccnd1 rescued cell cycle abnormalities observed in Insm1-deficient β-cells. We conclude that decreases in Insm1 interfere with β-cell specification during the early postnatal period and impair glucose homeostasis during metabolic stress in adults. Insm1 levels are therefore a factor that can influence the development of diabetes.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30257979     DOI: 10.2337/db17-1330

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  1 in total

Review 1.  Insulinoma-Associated-1: From Neuroendocrine Tumor Marker to Cancer Therapeutics.

Authors:  Chiachen Chen; Abner L Notkins; Michael S Lan
Journal:  Mol Cancer Res       Date:  2019-05-21       Impact factor: 5.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.